|
|
|
|
| LEADER |
00000czm a2200000 i 4500 |
| 005 |
20230412160242.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
201002s2020 si ob 000 0 eng d |
| 011 |
|
|
|a Z3950 Search: @or @attr 1=7 "9789811579172" @attr 1=7 "9789811579189"
|
| 011 |
|
|
|a Z3950 Record: 0 of 11
|
| 020 |
|
|
|a 9811579172
|q Internet
|
| 020 |
|
|
|a 9789811579172
|q Internet
|
| 020 |
|
|
|a 9811579180
|q Internet
|
| 020 |
|
|
|a 9789811579189
|q Internet
|
| 035 |
|
|
|a (OCoLC)1198557673
|
| 035 |
|
|
|a (EDS)EDS26589728
|
| 037 |
|
|
|a com.springer.onix.9789811579189
|b Springer Nature
|
| 040 |
|
|
|a YDX
|b eng
|e rda
|c YDX
|d GW5XE
|d EBLCP
|d OCLCF
|d OCLCO
|d NLW
|d UKMGB
|d OCLCQ
|d COM
|d Z5A
|
| 050 |
|
4 |
|a RA644.C67
|
| 082 |
0 |
4 |
|a 616.2414
|2 23
|
| 099 |
|
|
|a 616.2414 KUM
|
| 100 |
1 |
|
|a Kumar, Amit,
|e author.
|9 302789
|
| 245 |
1 |
0 |
|a Novel Coronavirus 2019 :
|b in-silco vaccine design and drug discovery /
|c Amit Kumar, Ajit Kumar Saxena, Gwo Giun (Chris) Lee, Amita Kashyap, G. Jyothsna.
|
| 246 |
3 |
|
|a Novel Coronavirus twenty nineteen
|
| 264 |
|
1 |
|a Singapore :
|b Springer,
|c 2020.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a SpringerBriefs in applied sciences and technology, Forensic and medical bioinformatics
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
|
|a Intro -- Preface -- Contents -- 1 Insights of NCoV 19 and COVID19 -- 1.1 Symptoms and Characteristics of COVID19 -- 1.2 Statistics of COVID19 -- 1.3 SARS Corona Virus 2 -- 1.4 World Health Organization Response towards COVID19 -- References -- 2 Genomics and Evolution of Novel Corona Virus 2019 -- 2.1 Important Regions Within the Novel Corona Virus Genome [2] -- 2.2 Linking NCoV with SARS and determining its genomic conservation -- References -- 3 Comparing Proteomics of NCoV 19 and MERS Corona Virus -- 3.1 ORF1ab Protein Sequence comparison of NCoV and MERS CoV --
|
| 505 |
8 |
|
|a 3.2 Comparison of Spike (S) Proteins of NCoV and MERS CoV -- 3.3 Comparison of Membrane (M) Proteins of NCoV and MERS CoV -- 3.4 Comparison of Envelope (E) Proteins of NCoV and MERS CoV -- 3.5 Comparison of Nucleocapsid (N) Proteins of NCoV and MERS CoV -- 3.6 Conclusion -- References -- 4 Physiochemical Characterization and Domain Annotation of ORF1ab Polyprotein of Novel Corona Virus 19 -- 4.1 Physiochemical Characterization of ORF1ab Polyprotein Using Protparam -- 4.2 Identification of Domains within the ORF1ab Polyprotein using SMART -- 4.3 The region 4406-5900 of ORF1ab polyprotein of NCoV --
|
| 505 |
8 |
|
|a 4.4 The Secondary Structural Conformations of the Region 4406-5900 -- 4.5 3D Structure prediction using Phyre -- 4.6 3D Structure Visualization of the SARS Corona Virus 2 RNA-Dependent RNA Polymerase Protein in RASMOL -- 4.7 Prediction of Disordered Sites Within the Protein Structure Based on GLOBPLOT -- References -- 5 Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV -- 5.1 Selection Criteria for Chemicals -- 5.2 Docking of the Chemicals in HEX -- 5.3 Docking Results Summarized -- References -- 6 Herbal Treatment Approach Towards COVID19 --
|
| 505 |
8 |
|
|a 6.1 Some of the Medicinal Plants in the COVID Therapy -- 6.2 Zingiber Officinale/Ginger -- 6.3 Allium Sativum/Garlic -- 6.4 Tinospora Cordifolia/Giloy -- 6.5 Ocimum Tenuiflorum/Tulsi and Withania Somnifera/Ashwaganda -- References -- 7 Evolutionary and Structural Studies of NCoV and SARS CoV-Spike proteins and their association with ACE2 Receptor -- 7.1 Introduction -- 7.2 Materials and Methods -- 7.2.1 Collection of Sequences -- 7.2.2 Phylogenetic Analysis -- 7.2.3 Protein Structure Homology Modeling by ITASSER -- 7.2.4 Protein-Protein Docking --
|
| 505 |
8 |
|
|a 7.2.5 Structural and Functional Analysis of NCoV 19 and SARS-CoV Using Human ACE2 -- 7.3 Results -- 7.4 Discussion -- 7.5 Conclusion -- References -- 8 Plasma Therapy Towards COVID Treatment -- 8.1 Assessing Global Success Rate of Plasma Therapy -- 8.2 Plasma Therapy Guidelines and Significance in India -- References -- 9 Identification of potential Vaccine Candidates for COVID19 -- 9.1 Determining the Foreignness of ORF1ab Poly Protein of Novel Corona Virus to Human Proteome Using BLAST -- 9.2 Identification of Antigenic Regions Using PVS -- 9.3 Antigenic Site Prediction by EMBOSS ANTIGENIC.
|
| 588 |
|
|
|a Machine converted from AACR2 source record.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed November 12, 2020).
|
| 650 |
|
0 |
|a COVID-19 (Disease)
|9 381126
|
| 650 |
|
0 |
|a COVID-19 (Disease)
|x Treatment.
|9 704588
|
| 650 |
|
0 |
|a COVID-19 (Disease)
|x Chemotherapy.
|
| 650 |
|
0 |
|a Drugs
|x Design.
|9 326775
|
| 650 |
|
0 |
|a Vaccines.
|9 325461
|
| 700 |
1 |
|
|a Saxena, Ajit Kumar,
|e author.
|9 1244144
|
| 700 |
1 |
|
|a Lee, Gwo Giun,
|e author.
|
| 700 |
1 |
|
|a Kashyap, Amita,
|e author.
|9 838558
|
| 700 |
1 |
|
|a Jyothsna, G.
|q (Gundlapally),
|e author.
|9 508890
|
| 776 |
0 |
8 |
|i Print version:
|a Kumar, Amit.
|t Novel Coronavirus 2019.
|d Singapore : Springer, 2020
|z 9811579172
|z 9789811579172
|w (OCoLC)1176320798
|
| 776 |
1 |
8 |
|w (OCoLC)1202462387
|w (OCoLC)1202480339
|
| 830 |
|
0 |
|a SpringerBriefs in applied sciences and technology.
|p Forensic and medical bioinformatics.
|9 838564
|
| 856 |
4 |
0 |
|u https://ezproxy.aut.ac.nz/login?url=https://link.springer.com/10.1007/978-981-15-7918-9
|z Springer eBooks
|x TEMPORARY ERM URL
|
| 942 |
|
|
|c EB
|n 0
|
| 999 |
|
|
|c 1802421
|d 1802421
|
